To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
165
Topical ocular application
Topical ocular application
Topical ocular application
Sall Research Medical Center
Artesia, California, United States
USC Department of Ophthalmology
Los Angeles, California, United States
Wolstan Eye Associates
To investigate the dose-response relationship of DE-104 in lowering intraocular pressure (IOP)
Time frame: 28 days
To compare the safety and efficacy of DE-104 ophthalmic solution with placebo and 0.005% latanoprost.
Time frame: 35 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
placebo
Topical ocular application
Torrance, California, United States
East Florida Eye Institute
Stuart, Florida, United States
Seidenberg Protzko Eye Associates
Bel Air, Maryland, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Rochester Ophthalmological Group, PC
Rochester, New York, United States
Cornerstone Eye Care
High Point, North Carolina, United States
Associated Glaucoma Consultants
Philadelphia, Pennsylvania, United States
Keystone Research, Ltd.
Austin, Texas, United States
...and 4 more locations